Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Mitral Valve Prolapse III: Nursing Management01:19

Mitral Valve Prolapse III: Nursing Management

The nursing management of Mitral Valve Prolapse, or MVP, centers around patient education, symptom monitoring, and lifestyle modifications.Patient Education on MVP Diagnosis and Heredity: Nurses should provide comprehensive education about MVP, a condition where the mitral valve does not close appropriately during heartbeats. This education often includes the condition's pathophysiology, symptoms, and potential complications, like arrhythmias or mitral regurgitation. Though not fully...
Mitral Valve Prolapse II: Assessment and Management01:22

Mitral Valve Prolapse II: Assessment and Management

IntroductionA range of clinical features characterizes Mitral Valve Prolapse (MVP), but it is important to note that many individuals with MVP are asymptomatic and may remain so throughout their lives. For those who do exhibit symptoms, the following are the key clinical features:Palpitations: This is a common symptom where individuals feel an irregular or rapid heartbeat. Palpitations in MVP are often due to arrhythmias such as premature ventricular contractions or supraventricular tachycardia.
Rheumatic Heart Disease III: Medical Management01:21

Rheumatic Heart Disease III: Medical Management

Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
Mitral Stenosis III: Medical Management01:26

Mitral Stenosis III: Medical Management

Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...
Mitral Regurgitation III: Medical Management01:25

Mitral Regurgitation III: Medical Management

Mitral regurgitation (MR) is characterized by retrograde blood circulation from the left ventricle into the left atrium due to inadequate mitral valve closure. The severity of the condition, symptoms, and underlying cause determine treatment strategies.Monitoring and Pharmacological TreatmentPatients with mild to moderate MR typically do not need immediate intervention but regular monitoring to assess progression and guide treatment. Patients with mild MR should have an echocardiogram every 3-5...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Differential effects of atorvastatin on calcification in stromal and vascular cells within monolayer and 3D plaque cap models.

Biochemical and biophysical research communications·2026
Same author

Tandem VR<sup>TM</sup> in Hospice Care: Exploring Pilot Data for Patient-Caregiver Dyads.

The American journal of hospice & palliative care·2026
Same author

Factors influencing patients to choose one obesity treatment over another: a qualitative study.

International journal of obesity (2005)·2025
Same author

Intra-temporal and intracranial radiological abnormalities in cochlear implantation.

Irish medical journal·2025
Same author

Patient perceptions of success in obesity treatment: An IMI2 SOPHIA study.

Obesity science & practice·2024
Same author

The <i>Tandem VR™</i> protocol: Synchronized nature-based and other outdoor experiences in virtual reality for hospice patients and their caregivers.

Contemporary clinical trials communications·2024

Related Experiment Video

Updated: Jun 17, 2026

An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause
06:18

An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause

Published on: August 13, 2019

Menopause management: a cardiovascular risk-based approach.

C J Haines1, E Farrell

  • 1Department of Obstetrics and Gynaecology, The Chinese University of Hong Kong, New Territories, Hong Kong.

Climacteric : the Journal of the International Menopause Society
|December 17, 2009
PubMed
Summary

Hormone replacement therapy (HRT) can safely manage menopausal symptoms, even in women with cardiovascular risks. Individualized HRT approaches improve cardiovascular health and menopausal symptom control.

More Related Videos

A Method to Study the Impact of Chemically-induced Ovarian Failure on Exercise Capacity and Cardiac Adaptation in Mice
14:26

A Method to Study the Impact of Chemically-induced Ovarian Failure on Exercise Capacity and Cardiac Adaptation in Mice

Published on: April 7, 2014

Related Experiment Videos

Last Updated: Jun 17, 2026

An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause
06:18

An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause

Published on: August 13, 2019

A Method to Study the Impact of Chemically-induced Ovarian Failure on Exercise Capacity and Cardiac Adaptation in Mice
14:26

A Method to Study the Impact of Chemically-induced Ovarian Failure on Exercise Capacity and Cardiac Adaptation in Mice

Published on: April 7, 2014

Area of Science:

  • Cardiology
  • Gynecology
  • Endocrinology

Background:

  • Menopausal symptom management is evolving beyond symptom control to include broader women's health aspects.
  • Hypertension and cardiovascular disease (CVD) risk are critical unmet needs for postmenopausal women, particularly in the Asia-Pacific region.
  • Gynecologists are key in assessing menopausal women's health, offering lifestyle advice, and guiding treatment or specialist referrals.

Purpose of the Study:

  • To summarize evidence on managing menopausal symptoms and cardiovascular risk in postmenopausal women.
  • To provide a treatment algorithm for individualized hormone replacement therapy (HRT) based on cardiovascular risk.
  • To assist physicians in decision-making for women with varying cardiovascular risk levels and diabetes.

Main Methods:

  • Review of available evidence by gynecologists and cardiologists.
  • Development of a flexible blood pressure classification strategy.
  • Creation of a treatment algorithm for individualized HRT.

Main Results:

  • Individualized HRT, tailored to cardiovascular risk, can effectively manage menopausal symptoms.
  • This approach may lead to improvements in cardiovascular health outcomes.
  • The algorithm assists in managing women with low, moderate, high cardiovascular risk, and those with diabetes.

Conclusions:

  • Individualized HRT is a viable strategy for managing menopausal symptoms while addressing cardiovascular health.
  • Flexible blood pressure classification aids in personalized treatment decisions.
  • This approach supports comprehensive care for postmenopausal women, especially in high-risk regions.